Startseite
Märkte
Charts & Ideen
Algo
Nachrichten
Store
Broker
Herunterladen
Wirtschaftskalender
Handelssignale
WebTerminal
Geben Sie
/
ein, um zu suchen: @user, $symbol
Suche
Einloggen
Eröffnen Sie ein Konto
Deutsch
English
Русский
中文
Español
Português
日本語
한국어
Français
Italiano
Türkçe
TSHA
#1815
Taysha Gene Therapies, Inc. Common Stock
4.5
3
+0.44%
Sektor:
Basis:
Gewinnwährung:
Tagesspanne
Jahresspanne
Tagesänderung
+0.44%
Monatliche Änderung
-4.43%
6 month change
+51.51%
Jahresänderung
+177.91%
Vorheriger Schlusskurs
4.5
1
Open
4.5
3
Bid
Ask
Low
4.5
3
High
4.5
3
Volumen
115
Märkte
Aktien
Gesundheitswesen
TSHA
Open full chart
Financials
Overview
Finanzbericht
Statistics
Dividends
Quarterly
Annual
Value
Q3, 24
Q4, 24
Q1, 25
Q2, 25
Q3, 25
TTM
Key stats
Total common shares outstanding
204.94 M
205 M
214.66 M
272.79 M
273.92 M
—
Valuation ratios
Enterprise value
254.25 M
215.62 M
181.79 M
317.4 M
598.37 M
1.31 B
Price to earnings ratio
5.91
-4.81
-4.09
-6.79
-9.91
-25.6
Price to sales ratio
35.12
51.93
49.49
77.07
140.37
318.86
Price to cash flow ratio
5.06
5.33
4.24
7.61
11.23
28.41
Price to book ratio
1.2
6.05
1.08
1.39
1.68
10.2
Enterprise value to EBITDA ratio
—
—
—
—
—
—
Profitability ratios
Return on assets %
0.14
0.12
0.16
0.08
0.1
0.46
Return on equity %
0.29
0.26
0.39
0.11
0.15
0.91
Return on invested capital %
257.93
221.99
263.06
359.78
441.35
1 286.18
Gross margin %
100
100
100
100
—
—
Operating margin %
1 448.43
985.76
930.54
1 347.08
—
—
EBITDA margin %
—
—
—
—
—
—
Net margin %
1 427.52
929.03
935.23
1 353.58
—
—
Liquidity ratios
Quick ratio
—
—
—
—
—
—
Current ratio
5.51
5.42
5.35
12.48
10.48
33.72
Inventory turnover
—
—
—
—
—
—
Asset turnover
0.01
0.01
0.02
0.01
0
0.04
Solvency ratios
Debt to assets ratio
—
—
—
—
—
—
Debt to equity ratio
—
—
—
—
—
—
Long term debt to total assets ratio
0.24
0.27
0.31
0.12
0.16
0.86
Long term debt to total equity ratio
0.48
0.61
0.77
0.17
0.23
1.78
Per share metrics
Operating cash flow per share
0.08
0.07
0.08
0.07
0.07
0.29
EBIT per share
—
—
—
—
—
—
EBITDA per share
—
—
—
—
—
—
Total debt per share
—
—
—
—
—
—
Cash per share
0.59
0.56
0.43
1.05
0.84
2.88
Net current asset value per share
0.6
0.57
0.45
1.06
0.85
2.93
Tangible book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Working capital per share
0.49
0.46
0.36
0.98
0.77
2.57
Book value per share
0.33
0.29
0.2
0.83
0.62
1.94
Nachrichten
Taysha Gene Therapies: F&E-Leiter verkauft Aktien im Wert von 942.000 US-Dollar
Neurogene: Stifel bekräftigt "Buy"-Rating und verweist auf solide Sicherheitsmarge
Stifel reiterates Buy rating on Neurogene stock, cites viable safety margin
Rett-Syndrom: Taysha behandelt ersten Patienten in zulassungsrelevanter Gentherapie-Studie
Taysha doses first patient in pivotal Rett syndrome gene therapy trial
Autolus Therapeutics: Needham hebt Kursziel an – Aktie legt deutlich zu
Taysha Gene Therapies: Aktie erreicht 52-Wochen-Hoch bei 5,98 US-Dollar
Taysha Gene Therapies stock hits 52-week high at $5.98
Biotech-Aktien: Jefferies nennt seine 6 Top-Picks für 2026/n
Biotech Stocks: Jefferies Names its 6 Top Picks for 2026
Taysha Gene Therapies: Citizens bekräftigt "Market Outperform"-Rating
Citizens reiterates Market Outperform rating on Taysha Gene Therapies stock